Filing Details
- Accession Number:
- 0001567619-22-020466
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-16 17:00:11
- Reporting Period:
- 2022-11-14
- Accepted Time:
- 2022-11-16 17:00:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1556270 | Jay Jonathan Mazelsky | One Idexx Drive Westbrook ME 04092 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-11-14 | 18,998 | $62.00 | 81,305 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-11-14 | 972 | $433.37 | 80,333 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-11-14 | 6,385 | $434.26 | 73,948 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-11-14 | 2,543 | $435.07 | 71,405 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-11-14 | 600 | $435.88 | 70,805 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2022-11-14 | 18,998 | $0.00 | 18,998 | $62.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-02-13 | No | 4 | M | Direct |
Footnotes
- Represents the weighted average price of the shares sold ranging from a low of $432.67 to a high of $433.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $433.69 to a high of $434.685 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $434.70 to a high of $435.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $435.77 to a high of $436.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Grant of option to buy 9,499 shares of Issuer common stock that became exercisable for 8,244 shares in four equal annual installments beginning February 14, 2015 and for the remaining 1,255 shares on February 14, 2019 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Not applicable.
Billionaire Hedge Funds
